Hemab Therapeutics (NASDAQ:COAG) Reaches New 52-Week High – Time to Buy?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) hit a new 52-week high on Thursday . The stock traded as high as $52.29 and last traded at $51.07, with a volume of 38258 shares. The stock had previously closed at $50.09.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on COAG shares. Wedbush restated an “outperform” rating and set a $55.00 price objective (up from $42.00) on shares of Hemab Therapeutics in a report on Monday, July 13th. Jefferies Financial Group lifted their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. HC Wainwright upped their price target on shares of Hemab Therapeutics from $40.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $48.00.

Hemab Therapeutics Stock Performance

The business’s 50 day moving average price is $36.52. The stock has a market cap of $2.32 billion and a price-to-earnings ratio of -2.07.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that Hemab Therapeutics Holdings, Inc. will post -2.89 EPS for the current year.

Insider Transactions at Hemab Therapeutics

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of Hemab Therapeutics stock in a transaction on Tuesday, June 16th. The stock was bought at an average cost of $24.98 per share, with a total value of $1,536,844.54. Following the transaction, the insider owned 6,444,637 shares of the company’s stock, valued at $160,987,032.26. This represents a 0.96% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have purchased 118,723 shares of company stock worth $2,957,781.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.